https://www.biopharmadive.com/news/peter-marks-fda-sarepta-disagree-rift-elevidys-review/719480/
just doing a bit of reading. Missed the discussion around this recent approval. Good to see actions matching the blah blah blah we value patient voice. Having these ADCOM meetings & other forums videoed & placed on u-tube is good IMO.
https://www.biopharmadive.com/news/peter-marks-fda-sarepta-disagr...
-
- There are more pages in this discussion • 1,716 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.015(1.04%) |
Mkt cap ! $1.661B | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.46 | $1.40 | $3.815M | 2.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11031 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 14844 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |